tbuckley/cabot-search huggingface dataset:
Systemic Effects Of Vitamin D
Authors: H Reichel
Journal: Annual Review of Medicine (1989)

Traditionally perceived as a seco-steroid hormone involved in the regulation of calcium metabolism, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] is now known also to be active in tissues not directly contributing to mineral metabolism. New data show that 1α,25(OH)2D3 is produced by and interacts with hematopoietic cells. The hormone promotes myeloid differentiation and modulates the function of activated lymphocytes. Another new target tissue for 1α,25(OH)2D3 is the skin, where 1α,25(OH)2D3 enhances differentiation of epidermal cells. Therapeutic application of 1α,25(OH)2D3 or suitable analogues in differentiation disorders of hematopoietic and skin cells is currently under investigation.
SATIRE
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gastric Surgery
Authors: Frank H. Lahey
Journal: New England Journal of Medicine (1946)

SINCE this paper is presented before and will be read largely by physicians interested in the general practice of medicine, in it I will try to cover briefly many of the conditions in which surgery is applicable in the stomach, duodenum and jejunum, and our experiences with them. The latter two structures will be included because their surgical management, either by subtotal gastrectomy or by gastroenterostomy, involves the stomach at the time of the primary surgical procedure and even more seriously involves it when secondary complications, such as gastrojejunal ulcer and gastrojejunocolic fistulas, occur.Hiatus HerniaIf we consider gastric . . .
Aktivere Krankenbe[ill]andlung in der Irrenanstalt.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3010: Thrombin Receptor Antagonist (TRA;SCH530348) is a Selective, Potent Inhibitor of PAR1 Activity with Predictable Pharmacokinetics
Authors: Lisa K Jennings, Angela Earhart, Richard C Becker, Larissa Reyderman, Enrico Veltri, Robert A Harrington
Journal: Circulation (2007)

Background: TRA-PCI was a multicenter, randomized, double-blind, placebo-controlled study demonstrating the safety of SCH 530348, a potent thrombin receptor antagonist (TRA), in patients undergoing non-urgent percutaneous coronary intervention (PCI). A secondary endpoint in a sub-study within the primary evaluable patient cohort was inhibition of platelet aggregation (IPA) induced by appropriate agonists relative to baseline. We hypothesized that TRA therapy would selectively inhibit platelet aggregation induced by the thrombin receptor agonist peptide (TRAP) and that sustained inhibition would be observed. Pharmacokinetic (PK) studies were also carried out. Methods: Platelet aggregation responses to TRAP, adenosine diphosphate (ADP), collagen and arachidonic acid (AA) were measured using light transmission aggregometry (LTA) at baseline, 30, 60, 90, 120 min following a loading dose (10, 20 or 40 mg vs placebo) and after a maintenance dose (0.5, 1.0 or 2.5 mg/day) at 30 and 60 days. PK was assessed at 30 and 60 min and 2 hr after loading dose administration. Results: TRA was active in inhibiting 15 μM TRAP-induced platelet aggregation with onset of inhibition directly related to dose. Loading doses of 10, 20 or 40 mg achieved &gt;90% inhibition of platelet aggregation (IPA) 60 –120 min post dose with the 40 mg dose achieving &gt;90% inhibition between 60 and 90 min. Patients receiving maintenance doses of 0.5, 1.0 or 2.5 mg exhibited &gt;90% IPA at 30 and 60 days. Placebo treated patients had on average ≥10% IPA to TRAP. TRA had no significant effects on ADP, collagen or AA -induced platelet aggregation compared with placebo controls. TRA PK was characterized by fast distribution and slow elimination (t1/2 = 165–311 hr) with clear evidence of hysteresis. Conclusion: Among PCI patients treated with TRA, there was a specific, dose-related, sustained inhibition of TRAP-induced platelet aggregation, without an impact on other aggregation related pathways. These data suggest that TRA is a potent, selective inhibitor of PAR-1 activity induced by thrombin activation of platelets, and, in view of this, is a promising therapeutic utility for treatment of thrombosis.
Continuity counts
Authors: E. W. Campion
Journal: JAMA (1984)

Continuity of care is one of those values that no one actually opposes but that is, nonetheless, often sacrificed quietly, usually in the name of convenience or efficiency. There are powerful forces making continuity of care increasingly difficult to achieve. Subspecialization fragments care. Third-party payment structures provide few incentives to support primary care givers developing strong patient relationships over time. Much of our health care system is discontinuous. Multiple levels of health care facilities hinder continuity of care. Urbanization and mobility also work against continuity of medical care. The American health consumer may even be placing convenience before continuity. The rapidly growing chains of medical walk-in centers entice consumers with advertisements of speed and convenience. The fast-food style of providing medical care is the antithesis of continuity of care. Even in more traditional settings, continuity of care may be difficult to achieve when patients see multiple specialists, often on self-referral.
Bureau of Legal Medicine and Legislation
Journal: JAMA (1946)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is affective illness on the increase?
Authors: J. Callan
Journal: JAMA (1979)

Affective illness, a many-faceted disorder, is the third most common condition diagnosed in the United States today (after cardiovascular and musculoskeletal disease), says Danielle Turns, MD, associate professor of psychiatry, University of Louisville. Speaking at a seminar on the Biology and Psychopharmacology of Depression in Tarpon Springs, Fla recently, Turns said that although accurate incidence and prevalence rates are difficult to establish, the prevalence of affective illness appears to be rising, and probably 17% of the US population suffers from it at present. The chance of someone who lives to age 70 contracting depression during his lifetime is now 7.8% for males and 20% for females. Just as many criteria for diagnosis are vague, the reasons for the increased prevalence are also unclear, said Turns. A portion of the statistical rise may result from more diagnoses of affective illness by physicians; part may be due to increased patient sophistication in
Disposition of 14 C and/or 74 As-Cacodylic Acid in Rats after Intravenous, Intratracheal, or Peroral Administration
Authors: J. T. Stevens, L. L. Hall, J. D. Farmer, L. C. DiPasquale, N. Chernoff, W. F. Durham
Journal: Environmental Health Perspectives (1977)

The distribution, excretion, and possible metaboism of 14C-and/or 74As-cacodylic acid, an organoar- senical herbicide, was studied in rats following a single intravenous injection, intratracheal instillation or oral gavage.Male Sherman rats were dosed at levels ranging from 200 mg/kg to 120 ,g/kg.The extent and rate of lung absorption was greater than gastrointestinal absorption.Concentrations in the liver and whole blood were higher after peroral dosing than intravenous administration.Levels observed in plasma and other tissues were similar after all three routes following the absorptive phase.The percent dose found in the whole blood, red blood cells, and plasma was similar for all doses given by these routes.Less than 0.1½ of the administered dose was recovered as "4CO2 by any route at 24 hr after administration.Twenty-four hours after intravenous, intratracheal, and peroral administration, 71, 60, and 25%, respec- tively, was excreted in the urine.After intravenous administration of 200 mg/kg, sufficient 14C-cacodyllc acid was recovered in bile to account for the small amount excreted in the feces.Cacodylic acid is probably not metabolized to inorganic arsenic since the disposition of 14C and 74As-cacodylic acid were identical.Kinetic analyses of the plasma curve for 14C-cacodylic acid (high dose) yielded three half-times; 0.014, 0.214 and 3.42 hr with an apparent volume of distribution of 15.3 ml.Highest initial concentrations were found in the whole blood, muscle, kidney, liver and lung.Levels in all tissues decreased rapidly, but remained high in whole blood.The red blood cells were found to be the major site of body burden of cacodylic acid.
Lymphedema Tarda
Authors: Charles M. Boyd
Journal: JAMA (1976)

<h3>To the Editor.—</h3> In a recent article by Segal and Turner (235:1996, 1976), an approach is described that "exemplifies the use of an interdisciplinary effort to achieve accurate diagnosis through readily available diagnostic procedures." We would like to add a comment regarding a useful and readily available diagnostic procedure that is not mentioned in their discussion: radionuclide lymphangiography. Although most frequently performed for the assessment of regional nodal involvement by neoplasms, radionuclide lymphangiography provides a very useful means of evaluating patients with lower extremity edema. The procedure essentially involves the subcutaneous administration of a radiocolloid (technetium Tc 99m sulfur colloid) and subsequent imaging of the lower extremities and pelvis with a gamma camera or rectilinear scanner, equipment available in any nuclear medicine service. The procedure is safe, simple, and lacks the technical difficulty added to the conventional roentgenographic lymphangiogram by severe edema. It is very suitable for outpatient application. The
Helicopter Evacuations
Authors: Alexander J. Jablonowski
Journal: JAMA (1985)

<h3>To the Editor.—</h3> Most medical directors of emergency air medical services would agree with the proposed national guidelines for the helicopter transport of patients as suggested by Drs Champion and Mattox.<sup>1</sup>Because of our experience, I disagree with the restriction to a single-purpose aircraft. Although emergency air medical service helicopters should have transport of patients as their first priority, it need not be their only priority. Programs that are fully integrated into regional emergency medical service networks will find themselves called on from time to time to help with air rescue. These vehicles may be the only suitable aircraft capable of reaching the rescue site in time. There are also some air medical services that support local public service agencies and do rescue work on a routine basis. National standards should not forbid this type of effort. I understand the concern of the American Society of Hospital-Based Emergency Air
HYALINE MEMBRANE DISEASE AND PULMONARY SURFACTANT
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Matthew H. Kulke, Charles S. Fuchs
Journal: Journal of Clinical Oncology (2008)

A further aspect is the investigation of new agents.In pancreatic cancer, new treatment strategies have predominantly been explored in the setting of first-line therapy.This is explained by the rather short survival of patients with metastatic pancreatic cancer.The trial by Kulke et al now indicates that capecitabine plus erlotinib is active in gemcitabine-pretreated patients. 1 These results suggest that this all-oral regimen may also be effective in first-line treatment of chemotherapy-naive patients.Currently, an ongoing German multicenter phase III study (ClinicalTrials.govIdentifier: NCT00440167) of the "Arbeitsgemeinschaft Internistische Onkologie" is randomly assigning patients with treatment-naive pancreatic cancer between a capecitabine ϩ erlotinib arm (using the same regimen like Kulke et al) and a gemcitabine ϩ erlotinib arm.
FINAL ACTION BY THE AMERICAN MEDICAL ASSOCIATION ON THE INSURANCE QUESTION.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stamping Out Breast Cancer
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pernicious Anemia.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Authors: Maurizio Mennini, Lamia Dahdah, Alessandro Fiocchi
Journal: New England Journal of Medicine (2017)

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisTo the Editor: The conclusions of Simpson and colleagues (Dec.15 issue) 1 regarding the effectiveness and quality-of-life-enhancing capacity of dupilumab in patients with atopic dermatitis open new perspectives in the strategies of treatment of allergic diseases, because interleukin-4 and interleukin-13 are "type 2 inflammatory cytokines that may be important drivers of atopic or allergic diseases."Given the good results in patients with asthma 2 or nasal polyposis, 3 we as pediatricians look with interest to the possibilities arising from these studies involving adults.However, the higher rate of allergic conjunctivitis in the dupilumab-treated population than in the placebo group in this trial runs against these wishes.Although we agree with the authors that "further studies on the causes of conjunctivitis are warranted," could these be cases of atopic keratoconjunctivitis rather than simple allergic conjunctivitis?This condition is often linked to atopic dermatitis. 4If so, could it be hypothesized that the blockage of interleukin-4 and interleukin-13 increases the activity of the specific ligands involved in atopic keratoconjunctivitis (e.g., the OX40 ligand) in the eye, an immunologically privileged area? 5 This would limit the potential uses of dupilumab in the allergy field.
Contents for This Section
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Hydroxyurea Exposure before Puberty on Sperm Parameters in Males with Sickle Cell Disease
Authors: Laure Joseph, Sandra Manceau, Corinne Pondarré, Anoosha Habibi, Francoise Bernaudin, Slimane Allali, Mariane De Montalembert, Céline Chalas, Jean Benoît Arlet, Camille Jean, Valentine Brousse
Journal: Blood (2019)